Novartis Ag

David Jenkins

Ming Lei

Andreas Loew

Li Zhou

Seth Alexander Ettenberg

Konstantin Petropoulos

Tiancen Hu

Nicole Haubst

Matthew John Meyer

Engin Toksoz

David Bryant Batt

Feng Cong

Karen Vincent

Philippe Thiel

Christy Fryer

Joelle Deplazes-Lauber

Tiacen Hu

The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.

Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)&#x2014;half life extender constructs

The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a Notch 3 or mutant Notch 3 receptor; and compositions and methods of use thereof.

Antibodies against notch 3

The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Antibody drug conjugates

The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding domains for two different binding sites of LRP6 and compositions and methods of use thereof.

Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies

Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs

Growing community of inventors

Carlisle, MA, United States of America

David Jenkins